CPhI Worldwide, organized by UBM, announced the finalists for the 2017 CPhI Pharma Awards. Winners will be announced-with 98 entries shortlisted-during this year’s CPhI Worldwide in Frankfurt, Germany.
The finalists have been selected from a record-breaking 200+ submissions-nearly double 2016’s total -received from 27 countries. There was fierce competition within the “Product Packaging” and “Drug Delivery and Devices” categories, receiving over 20 high-quality entries each.
The judging panel consists of 17 industry experts, crossing a diverse range of subject areas. The panel is chaired by Rita Peters, Editorial Director of Pharmaceutical Technology. The judges worked diligently through a large volume of applicants and unanimously reached an agreed list of finalists for each category. To access this list, please visit: http://awards.cphi.com/finalists/
Tara Dougal, Acting Head of Content at UBM commented, “The pharma industry is extremely competitive and it is important to provide wide recognition to the progress that is made in the industry every year. What was most impressive was the sheer volume of entries we received, and it therefore took us longer than usual to evaluate them all as we gave each entry the attention their efforts merited. I am grateful to all the companies that worked so hard to prepare a submission, as well as the judges for their time and attention, and I would like to congratulate the finalists for their achievements in this prestigious awards program. We wish them the best of luck.”
To reserve a table for the CPhI Pharma Awards Gala, please visit: http://awards.cphi.com/gala/#book-your-table.
Full list of award judges: Gil Roth (President, PBOA), Gary Norman (Technical Manager, DFE Pharma), Girish Malhotra (President, EPCOT International), Dr. Rene Boomer (General Manager, PharmAccel Consulting), Evonne Brennan (International Technical Marketing Manager, IMCD Ireland), Michael Platscher (Senior Project Manager R&D, Merck & Cie), Dr. Pascale Gauthier (Pharmacist PhD, Head of Course, Faculty of Pharmacy of Clermont-Ferrand), Rita Peters (Editorial Director, Pharmaceutical Technology), Adeline Siew (Editor, Pharmaceutical Technology Europe), Emil Ciurczak (President, Doramaxx Consulting), Dr. Dev Prasad (Senior Scientist in Formulation Development, Fresenius Kabi USA, LLC), Dr. Harsh Chauhan (Assistant Professor, Creighton University), Bikash Chatterjee (President and Chief Scientific Officer, Pharmatech Associates, Inc.), Alan Raymond (Non-Executive Director with Diurnal Ltd., Chairman of Anipoc Ltd., and Interim Chairman of ADC Bio Ltd.), Dan Stanton (Editor, BioPharma Reporter), Ger Standhardt (Manager – Knowledge Development & Projects, NVC Netherlands Packaging Centre) and lastly, Bibiana Campos Seijo (Editor-in-Chief and VP, C&EN and C&EN Media Group).
For more information visit: www.cphi.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.